BGMS

Business Context and Reporting Period

Company: Cyclacel Pharmaceuticals, Inc. (formerly Xcyte Therapies, Inc.)
Filing Type: Form 10-K
Period Ended: December 31, 2006
Business Overview: Cyclacel is a development-stage biopharmaceutical company focused on discovering and developing mechanism-targeted drugs for cancer and other serious disorders. The company's core expertise lies in cell cycle biology. It operates research facilities in Berkeley Heights, New Jersey; Dundee, Scotland; and Cambridge, England.

Corporate History: In March 2006, the company completed a reverse acquisition of Cyclacel Limited (via Xcyte Therapies, Inc.), changing its name to Cyclacel Pharmaceuticals, Inc. This transaction was accounted for as a reverse acquisition, with Cyclacel Limited considered the accounting acquirer. The company also sold its T-cell expansion technology ("Xcellerate Process") to Invitrogen for $5 million in March 2006.

Key Financial Metrics

Debt and Liquidity: The company has no significant long-term debt. Total liabilities were $9.36 million as of December 31, 2006, primarily consisting of accrued liabilities and restructuring charges. The company raised $42.6 million in net proceeds via a private placement in April 2006 and assumed $17.9 million in cash from the reverse acquisition.

Material Changes vs. Prior Period

• Revenue: Total revenue increased slightly by 8.7% to $0.39 million in 2006 compared to $0.36 million in 2005. This was driven by a 40.5% increase in grant revenue, partially offset by a 5.7% decrease in collaboration revenue.
• Expenses: Operating expenses increased significantly by 59.9% to $33.75 million in 2006 from $21.13 million in 2005.
  • R&D Expenses: Increased 33.9% to $21.21 million, primarily due to a $6.5 million increase in stock-based compensation and increased spending on the CYC116 program and Phase IIb trials for seliciclib.
  • G&A Expenses: Increased 132.9% to $12.32 million, driven by the costs of operating as a public company, increased compensation, and the integration of the Xcyte entity.
• Stock-Based Compensation: The adoption of SFAS 123R in 2006 resulted in a $9.6 million charge, compared to a credit of $0.33 million in 2005 under the previous accounting standard (APB 25).
• Liquidity: Cash and cash equivalents surged from $3.12 million in 2005 to $44.24 million in 2006, largely due to the private placement and the reverse acquisition.

Guidance, Outlook, and Risks

Outlook and Guidance:

• The company expects to continue incurring substantial losses for the next several years as it advances clinical trials.
• Management believes existing resources are sufficient to fund operations for at least the next 12 months (as of the filing date).
• Key milestones include reporting data from the seliciclib Phase IIb trial (APPRAISE) in Q4 2007 and commencing a Phase II trial for nasopharyngeal carcinoma in H2 2007.
• Phase II evaluation of sapacitabine in solid tumors and hematological malignancies is planned for H2 2007.

Risks and Contingencies:

• Development Risk: The company has no approved products and relies on the success of clinical trials for seliciclib, sapacitabine, and CYC116. Failure in these trials would be catastrophic.
• Capital Requirements: The company will need to raise substantial additional capital to fund operations beyond the next 12 months. Failure to secure funding could force delays or termination of programs.
• Intellectual Property: The company relies on licensed technology (e.g., seliciclib from CNRS/Institut Curie, sapacitabine from Sankyo). Termination of these licenses or infringement claims could harm the business.
• Restructuring Liability: The company has a $2.3 million accrued liability related to the Bothell, Washington facility lease, with potential additional accretion expenses.
• Derivative Liability: A $1.1 million liability exists related to the dividend make-whole feature of convertible preferred stock, which fluctuates with market conditions.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $54 million cash position to fund the planned Phase IIb and Phase II trials through 2007 and beyond.
• Clinical Trial Progress: Monitor the enrollment and interim data for the seliciclib APPRAISE trial and the sapacitabine Phase Ib/II trials.
• Capital Raising: Assess the company's ability to raise additional equity or debt financing given the high burn rate and lack of product revenue.
• Stock-Based Compensation: Review the impact of future stock option grants and vesting on future net losses under SFAS 123R.
• Restructuring Costs: Track the resolution of the Bothell facility lease and the associated $2.3 million liability.
• Preferred Stock Conversion: Monitor the terms of the convertible preferred stock, specifically the dividend make-whole feature and potential dilution upon conversion.